Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT06323356 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06323356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06323356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
March 19, 2024
Completion date
July 10, 2026
Enrollment
18 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

erythrodermic psoriasis, generalized pustular psoriasis